Canine Osteoarthritis: Diagnosis and Multimodal Management

At a Glance

Canine osteoarthritis (OA) is a progressive degenerative joint disease requiring systematic diagnosis and multimodal management. The table below summarizes core diagnostic and therapeutic components for veterinary practitioners.

Pathophysiology of Canine Osteoarthritis

Osteoarthritis involves the entire joint organ, with progressive loss of articular cartilage accompanied by changes in subchondral bone, synovium, and periarticular soft tissues. Mechanical stress, inflammatory mediators, and genetic factors contribute to OA initiation and progression. The Merck Veterinary Manual provides a comprehensive overview of OA pathophysiology in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/).

The disease process begins with disruption of the normal balance between cartilage synthesis and degradation. Chondrocytes become dysregulated and produce excessive matrix-degrading enzymes, particularly matrix metalloproteinases (MMPs), which break down collagen and proteoglycans. This leads to cartilage fibrillation, fissuring, and eventual erosion. Inflammatory cytokines, including interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha), are released from synovium and chondrocytes, amplifying the degradative cascade.

Subchondral bone undergoes remodeling with development of osteophytes at joint margins, a hallmark radiographic feature of OA. The synovium becomes inflamed (synovitis), contributing to joint effusion and pain. Periarticular fibrosis and muscle atrophy may develop as the disease progresses, further compromising joint function. A study published in Topics in Companion Animal Medicine reviewed the diagnosis and treatment of OA, emphasizing the multifactorial nature of the disease (Diagnosis and treatment of osteoarthritis, Topics in Companion Animal Medicine, 2010, https://pubmed.ncbi.nlm.nih.gov/20188335).

Clinical Signs and Diagnosis

History and Owner Observation

Diagnosis of canine OA begins with a thorough history. Owners often report subtle changes in behavior and activity level. Common observations include stiffness after rest, difficulty rising from a lying position, reluctance to jump or climb stairs, decreased playfulness, and lameness that may be intermittent or progressive. A study published in the Journal of Small Animal Practice evaluated the use of an owner-reported questionnaire and functional mobility tests for identifying canine OA and monitoring treatment (Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests, Journal of Small Animal Practice, 2022, https://pubmed.ncbi.nlm.nih.gov/35385129). This highlights the value of structured owner input in the diagnostic process.

Veterinarians should ask specific questions about onset, duration, and progression of signs. Factors such as age, breed, body condition score, and previous orthopedic injuries or surgeries are relevant. A history of trauma or developmental orthopedic disease (e.g., hip dysplasia, elbow dysplasia) increases OA risk. A study in Scientific Reports examined the prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs, underscoring that OA can develop early in life, particularly in predisposed breeds (Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs, Scientific Reports, 2024, https://pubmed.ncbi.nlm.nih.gov/38310147).

Physical Examination

A complete orthopedic and neurologic examination is essential. The examination should be systematic, evaluating each joint for pain, swelling, crepitus, range of motion, and instability. Gait analysis at walk and trot helps identify affected limbs and lameness severity. Joint palpation may reveal effusion, thickening of the joint capsule, and pain on manipulation.

The Merck Veterinary Manual provides detailed guidance on the orthopedic examination in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/). Specific tests, such as the Ortolani test for hip laxity and the drawer sign for cranial cruciate ligament rupture, help identify underlying conditions that predispose to OA. A study on canine elbow dysplasia and medial compartment disease highlights the importance of recognizing developmental conditions that lead to OA (Canine Elbow Dysplasia: Medial Compartment Disease and Osteoarthritis, Veterinary Clinics of North America: Small Animal Practice, 2021, https://pubmed.ncbi.nlm.nih.gov/33558016).

Diagnostic Imaging

Radiography is the most commonly used imaging modality for diagnosing OA. Standard views of affected joints should be obtained. Radiographic findings include joint space narrowing, osteophyte formation, subchondral bone sclerosis, and periarticular soft tissue swelling. The severity of radiographic changes does not always correlate with the degree of clinical pain or functional impairment.

Advanced imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), may be indicated for complex cases, particularly when surgical intervention is being considered. CT provides detailed assessment of bone architecture and is useful for evaluating elbow dysplasia and other developmental conditions. MRI offers superior visualization of soft tissues, including cartilage, ligaments, and menisci.

Synovial Fluid Analysis

Synovial fluid analysis can help differentiate OA from other causes of joint disease, such as septic arthritis or immune-mediated polyarthritis. In OA, the fluid is typically non-inflammatory, with a low nucleated cell count and normal viscosity. A study published in the Veterinary Record investigated canine synovial fluid biomarkers for early detection and monitoring of OA (Canine synovial fluid biomarkers for early detection and monitoring of osteoarthritis, Veterinary Record, 2017, https://pubmed.ncbi.nlm.nih.gov/28364073). While not yet routine in clinical practice, biomarker analysis may become a valuable tool for early diagnosis and treatment monitoring.

Multimodal Management

Pharmacologic Management

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs are a cornerstone of pharmacologic management for canine OA. They provide analgesia and reduce inflammation by inhibiting cyclooxygenase (COX) enzymes, particularly COX-2. Several NSAIDs are approved for use in dogs, including carprofen, meloxicam, deracoxib, firocoxib, and grapiprant. The choice of NSAID depends on individual patient factors, including age, breed, concurrent diseases, and concurrent medications.

The Merck Veterinary Manual provides information on NSAID use in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/). NSAIDs should be used with caution in patients with renal, hepatic, or gastrointestinal disease. Baseline blood work and urinalysis are recommended before initiating therapy, and periodic monitoring is advised during long-term use.

Adjunctive Analgesics

For patients with inadequate pain control on NSAIDs alone, adjunctive analgesics may be added. These include gabapentin, amantadine, and tramadol. Gabapentin is commonly used for neuropathic pain and may be beneficial in chronic OA. Amantadine is an N-methyl-D-aspartate (NMDA) receptor antagonist that can enhance the analgesic effect of NSAIDs. Tramadol is a weak mu-opioid agonist with additional serotonergic and noradrenergic activity, but its efficacy in dogs is variable.

A study published in Pain evaluated the use of daily cannabidiol (CBD) for the treatment of canine OA pain (A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain, Pain, 2020, https://pubmed.ncbi.nlm.nih.gov/32345916). While this study showed promise, CBD is not currently approved by the FDA for use in animals, and its use should be discussed with the owner, including potential risks and legal considerations.

Disease-Modifying Osteoarthritis Agents (DMOAAs)

DMOAAs are substances purported to slow OA progression by protecting cartilage or stimulating its repair. Examples include polysulfated glycosaminoglycan (PSGAG), pentosan polysulfate, and hyaluronic acid. These agents are administered by injection, either intramuscularly or intra-articularly. Evidence for their efficacy is variable, and they are often used as adjuncts to other therapies.

Joint Supplements

Joint supplements are widely used in the management of canine OA. Common ingredients include glucosamine, chondroitin sulfate, methylsulfonylmethane (MSM), omega-3 fatty acids, and eggshell membrane. The evidence for their efficacy is mixed, with some studies showing benefit and others showing no significant effect.

A study published in Frontiers in Veterinary Science examined demographic factors associated with joint supplement use in dogs from the Dog Aging Project (Demographic factors associated with joint supplement use in dogs from the Dog Aging Project, Frontiers in Veterinary Science, 2022, https://doi.org/10.3389/fvets.2022.906521). This research provides insights into which dogs are most likely to receive supplements.

Another study in Frontiers in Veterinary Science evaluated the efficacy of a joint supplement containing eggshell membrane among other ingredients to improve mobility in dogs with OA (Efficacy of a joint supplement containing eggshell membrane among other ingredients to improve the mobility of dogs with osteoarthritis: a multicenter double-blind randomized placebo-controlled study, Frontiers in Veterinary Science, 2025, https://doi.org/10.3389/fvets.2025.1561793). This multicenter, double-blind, randomized, placebo-controlled study provides evidence for the potential benefit of this specific formulation.

A study published in Topics in Companion Animal Medicine compared the effect of an oral joint supplement to carprofen in the management of hip OA in working dogs (Effect of an Oral Joint Supplement When Compared to Carprofen in the Management of Hip Osteoarthritis in Working Dogs, Topics in Companion Animal Medicine, 2017, https://doi.org/10.1053/j.tcam.2017.10.003). This study highlights the importance of comparing supplements to established pharmacologic therapies.

A pharmacokinetic analysis of an oral multicomponent joint dietary supplement (Phycox) in dogs was published in Pharmaceutics (Pharmacokinetic analysis of an oral multicomponent joint dietary supplement (Phycox®) in dogs, Pharmaceutics, 2017, https://doi.org/10.3390/pharmaceutics9030030). Understanding the pharmacokinetics of these products is important for determining appropriate dosing.

Joint supplements are not regulated by the FDA in the same manner as drugs. Quality control can vary between manufacturers. A case report published in Topics in Companion Animal Medicine described acute manganese toxicosis related to joint health supplement ingestion in two dogs (Acute manganese toxicosis related to joint health supplement ingestion in two dogs, Topics in Companion Animal Medicine, 2024, https://doi.org/10.1016/j.tcam.2024.100877). This underscores the potential for adverse effects and the importance of using reputable products.

Non-Pharmacologic Management

Weight Management

Obesity is a significant risk factor for the development and progression of OA. Excess body weight places increased mechanical stress on weight-bearing joints and contributes to systemic inflammation. Weight loss is one of the most effective interventions for managing OA in overweight dogs. A controlled weight loss program, including dietary modification and increased physical activity, should be implemented.

The Merck Veterinary Manual provides guidance on weight management in dogs (Merck Veterinary Manual, https://www.merckvetmanual.com/). Body condition scoring (BCS) is a useful tool for assessing and monitoring body weight.

Physical Therapy and Rehabilitation

Physical therapy plays a crucial role in the management of canine OA. Goals include improving joint range of motion, strengthening periarticular muscles, reducing pain, and improving function. Modalities include therapeutic exercises, manual therapy, hydrotherapy, and electrotherapy (e.g., therapeutic ultrasound, laser therapy, transcutaneous electrical nerve stimulation [TENS]).

A structured rehabilitation program should be tailored to the individual patient. Exercises may include passive range of motion, stretching, balance and proprioceptive training, and controlled walking or swimming. Hydrotherapy, such as underwater treadmill or swimming, provides low-impact exercise that can improve muscle strength and joint mobility.

Environmental Modifications

Simple environmental modifications can significantly improve quality of life for dogs with OA. Providing soft, supportive bedding can reduce pressure on painful joints. Ramps or steps can help dogs access furniture or vehicles. Non-slip flooring can improve traction and reduce the risk of falls. Raising food and water bowls can make eating and drinking more comfortable for dogs with neck or back pain.

Surgical Management

Surgical intervention may be indicated for dogs with severe OA unresponsive to medical management, or for those with underlying conditions that can be surgically corrected. Surgical options include:

• Joint debridement and lavage: Arthroscopic removal of loose cartilage fragments and inflammatory debris.
• Osteotomy: Realignment of bones to redistribute joint forces (e.g., tibial plateau leveling osteotomy [TPLO] for cranial cruciate ligament rupture).
• Joint replacement: Total hip replacement (THR) or total knee replacement (TKR) for end-stage OA.
• Arthrodesis: Surgical fusion of a joint to eliminate pain (e.g., carpal or tarsal arthrodesis).
• Amputation: Reserved for severe, non-reconstructable joint disease or when other options have failed.

The decision to pursue surgery should be made on a case-by-case basis, considering the patient's age, overall health, and the owner's expectations and resources. The American College of Veterinary Internal Medicine (ACVIM) provides resources on OA management (American College of Veterinary Internal Medicine, https://www.acvim.org/).

Practical Implementation Steps

Step 1: Establish a Diagnosis

• Obtain a thorough history, including owner observations and functional limitations.
• Perform a complete orthopedic and neurologic examination.
• Obtain radiographs of the affected joint(s).
• Consider advanced imaging (CT, MRI) for complex cases.
• Perform synovial fluid analysis if indicated.

Step 2: Assess Pain and Functional Impairment

• Use a validated pain assessment tool, such as the Canine Brief Pain Inventory (CBPI) or the Helsinki Chronic Pain Index.
• Evaluate the dog's gait, range of motion, and ability to perform daily activities.
• Assess the owner's perception of the dog's quality of life.

Step 3: Develop a Multimodal Treatment Plan

• Address underlying conditions (e.g., hip dysplasia, cruciate ligament rupture).
• Implement weight management if the dog is overweight or obese.
• Prescribe NSAIDs as a first-line pharmacologic therapy, with appropriate monitoring.
• Consider adjunctive analgesics (gabapentin, amantadine) for refractory pain.
• Recommend joint supplements, with a discussion of the evidence and potential risks.
• Initiate a physical therapy and rehabilitation program.
• Make environmental modifications to improve comfort and mobility.
• Discuss surgical options for severe or refractory cases.

Step 4: Monitor and Adjust the Treatment Plan

• Schedule regular recheck examinations to assess response to therapy.
• Repeat pain assessments and functional evaluations.
• Adjust medications and other therapies as needed.
• Monitor for adverse effects of medications.
• Communicate regularly with the owner to address concerns and adjust the plan.

Records and Measurements

Maintaining accurate records is essential for monitoring OA progression and treatment response. The following should be documented:

• History: Onset, duration, and progression of clinical signs, previous treatments and response.
• Physical examination findings: Gait analysis, joint palpation findings, range of motion, pain scores.
• Diagnostic imaging findings: Radiographic changes, advanced imaging results.
• Pain assessment scores: CBPI or other validated tool scores.
• Body weight and body condition score.
• Medications and supplements: Drug, dose, frequency, duration, and any adverse effects.
• Physical therapy and rehabilitation: Type, frequency, and duration of therapy.
• Owner observations: Changes in activity level, behavior, and quality of life.

Common Failure Patterns

Failure to Diagnose OA Early

OA is often diagnosed late in the disease process, when significant cartilage loss has already occurred. Early diagnosis is challenging because clinical signs may be subtle, and owners may attribute them to normal aging. Regular veterinary examinations, particularly for at-risk breeds, can help identify OA earlier.

Inadequate Pain Management

Many dogs with OA receive inadequate pain management. This may be due to underdosing of NSAIDs, failure to use adjunctive analgesics, or lack of a multimodal approach. Regular pain assessments and adjustments to the treatment plan are essential.

Poor Owner Compliance

Owner compliance with treatment recommendations can be a significant barrier to successful management. This may include failure to administer medications as prescribed, lack of adherence to weight management programs, or reluctance to pursue physical therapy. Clear communication and education are key to improving compliance.

Overreliance on a Single Modality

OA is a complex disease that requires a multimodal approach. Relying solely on NSAIDs or joint supplements is unlikely to provide optimal pain control and functional improvement. A comprehensive plan that includes pharmacologic, non-pharmacologic, and surgical interventions is necessary.

Failure to Address Underlying Conditions

OA is often secondary to an underlying condition, such as hip dysplasia, elbow dysplasia, or cranial cruciate ligament rupture. Failure to diagnose and address these conditions can lead to progressive joint damage and poor outcomes.

Limitations and Safety Context

Limitations of Current Evidence

The evidence base for many OA treatments is limited. Many studies are small, of short duration, or lack appropriate control groups. The heterogeneity of OA in dogs, including differences in etiology, severity, and affected joints, makes it difficult to generalize findings. Veterinarians should critically evaluate the available evidence and make treatment decisions on a case-by-case basis.

Safety Considerations

• NSAIDs: Potential adverse effects include gastrointestinal ulceration, renal toxicity, and hepatotoxicity. Use with caution in patients with pre-existing disease. Monitor renal and hepatic function periodically.
• Gabapentin: Sedation and ataxia are common adverse effects. Start with a low dose and titrate slowly.
• Amantadine: May cause gastrointestinal upset or central nervous system effects.
• Joint supplements: Quality control varies. Use reputable products. Be aware of the potential for adverse effects, such as manganese toxicosis.
• CBD: Not FDA-approved for use in animals. Potential for adverse effects and drug interactions. Discuss legal and safety considerations with owners.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary orthopedic specialist or a veterinary rehabilitation practitioner in the following situations:

• Severe or progressive OA not responding to medical management.
• Complex cases involving multiple joints or underlying developmental orthopedic disease.
• Surgical candidates for joint replacement, arthrodesis, or other advanced procedures.
• Patients requiring advanced diagnostic imaging (CT, MRI).
• Patients with refractory pain not controlled with standard therapies.
• Cases where physical therapy or rehabilitation is beyond the scope of the primary care veterinarian.

Practical Decision Framework for Selecting and Sequencing OA Therapies

A structured decision framework helps veterinarians systematically select and sequence therapies for canine osteoarthritis based on disease severity, patient factors, and treatment response. The framework below integrates clinical staging, treatment tiers, and objective reassessment intervals to guide clinical decision-making.

Clinical Staging System for Canine OA

Clinical staging provides a foundation for treatment selection. The system below uses owner-reported signs, physical examination findings, and functional assessments to categorize OA severity.

Stage 1: Early OA (Mild Clinical Signs)

• Owner reports subtle stiffness after rest, especially in the morning or after naps
• Dog remains active but shows slight hesitation when jumping or climbing stairs
• Physical examination reveals mild joint discomfort on full flexion or extension
• Radiographic changes may be minimal or absent
• Gait appears normal at a walk but may show subtle lameness at a trot

Stage 2: Moderate OA (Established Clinical Signs)

• Owner reports consistent stiffness after rest lasting several minutes
• Dog shows reluctance to jump onto furniture or into vehicles
• Lameness is noticeable after exercise or on cold days
• Physical examination reveals joint effusion, crepitus, and reduced range of motion
• Radiographic changes include osteophyte formation and joint space narrowing

Stage 3: Severe OA (Advanced Clinical Signs)

• Owner reports difficulty rising from lying position
• Dog shows persistent lameness or non-weight-bearing on the affected limb
• Activity level is significantly reduced
• Physical examination reveals marked joint thickening, severe crepitus, and muscle atrophy
• Radiographic changes include extensive osteophyte formation, subchondral bone sclerosis, and joint deformity

Stage 4: End-Stage OA (Debilitating Clinical Signs)

• Owner reports the dog is unwilling to walk more than short distances
• Dog shows constant discomfort or pain at rest
• Quality of life is significantly impaired
• Physical examination reveals severe joint deformity and near-complete loss of range of motion
• Radiographic changes include complete loss of joint space and bone remodeling

Treatment Tier Selection Based on Clinical Stage

The treatment tiers below correspond to the clinical stages described above. Each tier builds upon the previous one, adding therapies as disease severity increases.

Tier 1: Stage 1 OA (Early Disease)

• Weight management: Target body condition score (BCS) of 4-5 out of 9
• Joint supplements: Consider products with evidence of efficacy, such as those containing eggshell membrane (Efficacy of a joint supplement containing eggshell membrane among other ingredients to improve the mobility of dogs with osteoarthritis: a multicenter double-blind randomized placebo-controlled study, Frontiers in Veterinary Science, 2025, https://doi.org/10.3389/fvets.2025.1561793)
• Environmental modifications: Provide orthopedic bedding, use non-slip flooring, install ramps for furniture access
• Low-impact exercise: Controlled leash walks, swimming, or underwater treadmill sessions 3-4 times per week
• Omega-3 fatty acid supplementation: Incorporate into diet at therapeutic doses

Tier 2: Stage 2 OA (Moderate Disease)

• All Tier 1 interventions
• NSAID therapy: Initiate with appropriate COX-2 selective NSAID (carprofen, meloxicam, deracoxib, firocoxib, or grapiprant)
• Physical therapy: Begin structured rehabilitation program including passive range of motion exercises, stretching, and strengthening exercises
• Adjunctive analgesics: Consider gabapentin for neuropathic pain component
• Regular reassessment: Schedule recheck examination every 4-6 weeks until stable

Tier 3: Stage 3 OA (Severe Disease)

• All Tier 1 and Tier 2 interventions
• NSAID optimization: Ensure appropriate dosing and consider rotating NSAIDs if response is inadequate
• Adjunctive analgesics: Add amantadine or increase gabapentin dose as needed
• Injectable DMOAAs: Consider polysulfated glycosaminoglycan or pentosan polysulfate
• Advanced physical therapy: Increase frequency of rehabilitation sessions to 4-5 times per week
• Surgical consultation: Refer to veterinary orthopedic specialist for evaluation

Tier 4: Stage 4 OA (End-Stage Disease)

• All Tier 1, Tier 2, and Tier 3 interventions
• Intensive pain management: Consider multimodal analgesia including NSAIDs, gabapentin, amantadine, and potentially tramadol
• Surgical intervention: Discuss total joint replacement, arthrodesis, or amputation with owner
• Palliative care: Focus on comfort and quality of life
• Euthanasia discussion: When quality of life cannot be maintained despite maximal therapy

Sequencing Algorithm for Treatment Initiation

The algorithm below provides a step-by-step approach for initiating therapy in a newly diagnosed OA patient.

Step 1: Baseline Assessment (Day 0)

• Complete history and physical examination
• Obtain radiographs of affected joints
• Administer validated pain assessment tool (Canine Brief Pain Inventory or Helsinki Chronic Pain Index)
• Record body weight and BCS
• Document baseline functional mobility using timed up-and-go test or other objective measure

Step 2: Initiate Tier 1 Interventions (Day 0)

• Discuss weight management goals with owner
• Prescribe joint supplement with evidence of efficacy
• Provide environmental modification recommendations
• Develop low-impact exercise plan
• Schedule follow-up in 4 weeks

Step 3: Reassess at 4 Weeks

• Repeat pain assessment tool
• Measure body weight and BCS
• Evaluate owner-reported changes in activity and mobility
• If adequate response (pain score reduced by 30% or more): Continue Tier 1 and reassess in 8-12 weeks
• If inadequate response: Progress to Tier 2

Step 4: Initiate Tier 2 Interventions (Week 4)

• Prescribe NSAID after baseline blood work (CBC, chemistry panel, urinalysis)
• Begin physical therapy program
• Consider gabapentin if neuropathic pain component suspected
• Schedule follow-up in 4 weeks

Step 5: Reassess at 8 Weeks

• Repeat pain assessment tool and functional mobility tests
• Evaluate for NSAID adverse effects
• If adequate response: Continue Tier 2 and reassess in 8-12 weeks
• If inadequate response: Progress to Tier 3

Step 6: Initiate Tier 3 Interventions (Week 8)

• Optimize NSAID dosing or consider alternative NSAID
• Add amantadine or adjust gabapentin dose
• Consider injectable DMOAAs
• Increase physical therapy frequency
• Refer to orthopedic specialist for surgical evaluation
• Schedule follow-up in 4-6 weeks

Step 7: Reassess at 12-14 Weeks

• Comprehensive reassessment including pain scores, functional tests, and owner quality-of-life assessment
• If adequate response: Continue Tier 3 and reassess in 12 weeks
• If inadequate response: Progress to Tier 4

Step 8: Initiate Tier 4 Interventions (Week 12-14)

• Intensive multimodal analgesia
• Surgical intervention if appropriate candidate
• Palliative care measures
• Quality-of-life counseling with owner

Objective Reassessment Tools and Thresholds

Objective reassessment is essential for determining treatment response and guiding therapy adjustments. The tools and thresholds below provide measurable criteria for decision-making.

Canine Brief Pain Inventory (CBPI)

• Administer at each reassessment visit
• Threshold for adequate response: 30% reduction in pain severity score and 30% reduction in pain interference score from baseline
• Threshold for excellent response: 50% reduction in both scores

Functional Mobility Tests

• Timed up-and-go test: Measure time for dog to rise from lying to standing and walk 3 meters
• Threshold for improvement: 20% reduction in time from baseline
• Stair climbing test: Count number of stairs dog can climb in 30 seconds
• Threshold for improvement: 25% increase in stair count from baseline

Owner-Reported Outcomes

• Use structured questionnaire such as the Liverpool Osteoarthritis in Dogs (LOAD) instrument
• Threshold for improvement: 20% reduction in LOAD score from baseline
• Owner global assessment: Ask owner to rate dog's overall mobility on a 0-10 scale (0 = normal, 10 = severely impaired)
• Threshold for improvement: 2-point reduction from baseline

Body Weight and BCS

• Measure at each reassessment visit
• Target: 5-10% body weight reduction in overweight dogs (BCS 6-7/9)
• Target: 10-15% body weight reduction in obese dogs (BCS 8-9/9)

Record System for Tracking OA Management

A standardized record system ensures consistent documentation and facilitates treatment adjustments. The template below can be adapted for electronic medical records or paper charts.

Initial Visit Record (Day 0)

• Patient information: Name, age, breed, sex, weight, BCS
• Affected joints: List all joints with radiographic OA
• Clinical stage: 1, 2, 3, or 4
• Pain assessment scores: CBPI pain severity, CBPI pain interference, LOAD score
• Functional tests: Timed up-and-go, stair climb count
• Owner global assessment score
• Current medications and supplements
• Treatment plan: Tier level and specific interventions prescribed
• Follow-up interval: 4 weeks

Recheck Visit Record (Every 4-12 Weeks)

• Date and visit number
• Weight and BCS
• Pain assessment scores: Compare to baseline
• Functional tests: Compare to baseline
• Owner global assessment score
• Owner-reported adverse effects
• Medication compliance assessment
• Treatment response classification: Adequate, inadequate, or excellent
• Treatment adjustments: List any changes to medications, supplements, or therapies
• Next follow-up interval

Treatment Response Classification Criteria

• Adequate response: 30% reduction in CBPI pain severity and interference scores, 20% improvement in functional tests, owner global assessment improved by 2 points
• Excellent response: 50% reduction in CBPI scores, 25% improvement in functional tests, owner global assessment improved by 4 points
• Inadequate response: Less than 30% reduction in CBPI scores, less than 20% improvement in functional tests, owner global assessment improved by less than 2 points

Troubleshooting Common Treatment Failures

When a patient fails to achieve adequate response at a given treatment tier, the following troubleshooting approach can identify and address underlying issues.

Failure Pattern 1: Inadequate NSAID Response

• Possible causes: Incorrect dosing, inappropriate NSAID selection, concurrent disease affecting drug metabolism, or pain not primarily inflammatory
• Troubleshooting steps:
  1. Verify owner compliance with dosing instructions
  2. Confirm weight-based dosing is correct
  3. Consider switching to a different NSAID class (e.g., from carprofen to firocoxib)
  4. Evaluate for concurrent conditions (e.g., neuropathic pain, myofascial pain)
  5. Add adjunctive analgesic (gabapentin or amantadine)

Failure Pattern 2: Poor Owner Compliance

• Possible causes: Cost of medications, difficulty administering pills, lack of understanding of treatment goals, or perceived lack of benefit
• Troubleshooting steps:
  1. Discuss cost concerns and explore generic options or alternative formulations
  2. Demonstrate pill administration techniques
  3. Provide written instructions and treatment schedule
  4. Explain expected timeline for improvement (4-6 weeks for NSAIDs, 8-12 weeks for supplements)
  5. Schedule more frequent follow-up to maintain engagement

Failure Pattern 3: Weight Management Failure

• Possible causes: Owner reluctance to restrict food, multiple-pet household, or medical conditions causing weight gain
• Troubleshooting steps:
  1. Calculate exact daily calorie requirement and provide specific feeding instructions
  2. Recommend prescription weight management diet
  3. Address multiple-pet feeding strategies (separate feeding areas, timed feeders)
  4. Evaluate for hypothyroidism or other metabolic conditions
  5. Set realistic weight loss goals (1-2% body weight per week)

Failure Pattern 4: Exercise Intolerance

• Possible causes: Pain not adequately controlled, concurrent orthopedic or neurologic conditions, or cardiovascular disease
• Troubleshooting steps:
  1. Reassess pain control and adjust analgesics
  2. Perform complete orthopedic and neurologic examination
  3. Evaluate for concurrent conditions (e.g., cruciate ligament rupture, intervertebral disc disease)
  4. Modify exercise program to lower intensity (shorter walks, swimming instead of walking)
  5. Consider cardiac evaluation if exercise intolerance persists

Failure Pattern 5: Supplement Non-Response

• Possible causes: Inadequate dosing, poor bioavailability, or product quality issues
• Troubleshooting steps:
  1. Verify supplement contains evidence-based ingredients at therapeutic doses
  2. Check for expiration date and proper storage
  3. Consider switching to a different supplement formulation
  4. Evaluate for concurrent conditions that may limit response
  5. Discontinue supplement if no benefit after 12 weeks of consistent use

Professional Escalation Criteria for Treatment Failure

When troubleshooting fails to achieve adequate response, referral to a specialist is indicated. The criteria below guide escalation decisions.

Criteria for Orthopedic Specialist Referral

• Persistent lameness despite 8 weeks of Tier 3 therapy
• Radiographic evidence of severe joint disease (Stage 3 or 4)
• Suspected underlying developmental orthopedic disease (hip dysplasia, elbow dysplasia)
• Candidate for surgical intervention (joint replacement, arthrodesis)
• Need for advanced diagnostic imaging (CT, MRI)

Criteria for Rehabilitation Specialist Referral

• Inadequate response to basic physical therapy program
• Need for advanced rehabilitation modalities (therapeutic laser, extracorporeal shock wave therapy)
• Complex cases involving multiple joints or neurologic deficits
• Owner unable to implement home exercise program without professional guidance

Criteria for Pain Management Specialist Referral

• Refractory pain despite maximal multimodal therapy
• Suspected neuropathic pain component not responding to gabapentin or amantadine
• Need for interventional pain management techniques (epidural injections, nerve blocks)
• Concerns about medication adverse effects or drug interactions

Safety Considerations in Treatment Sequencing

When implementing the decision framework, veterinarians must consider safety at each treatment tier.

NSAID Safety Monitoring

• Baseline blood work (CBC, chemistry panel, urinalysis) before initiating NSAID therapy
• Recheck blood work 2-4 weeks after starting NSAID, then every 6-12 months
• Monitor for gastrointestinal signs (vomiting, diarrhea, decreased appetite)
• Contraindications: Concurrent corticosteroid use, renal disease, hepatic disease, gastrointestinal ulceration

Gabapentin Safety Considerations

• Start at low dose (5-10 mg/kg every 8-12 hours) and titrate slowly
• Monitor for sedation and ataxia, especially in geriatric patients
• Avoid abrupt discontinuation, taper over 1-2 weeks
• Use with caution in patients with renal disease

Amantadine Safety Considerations

• Standard dose: 3-5 mg/kg once daily
• May cause gastrointestinal upset, administer with food
• Monitor for central nervous system effects (agitation, disorientation)
• Contraindicated in patients with seizure disorders

Joint Supplement Safety Considerations

• Use products from reputable manufacturers with quality control testing
• Be aware of potential for heavy metal contamination (Acute manganese toxicosis related to joint health supplement ingestion in two dogs, Topics in Companion Animal Medicine, 2024, https://doi.org/10.1016/j.tcam.2024.100877)
• Monitor for gastrointestinal upset when initiating supplements
• Discontinue if no benefit after 12 weeks of consistent use

Limitations of the Decision Framework

The decision framework provides a structured approach to OA management, but several limitations should be acknowledged.

Individual Patient Variability

• Dogs may not fit neatly into clinical stages
• Response to therapy varies widely between individuals
• Concurrent conditions may complicate treatment decisions

Evidence Gaps

• Limited evidence for optimal sequencing of therapies
• Few studies directly compare different treatment combinations
• Long-term outcomes for many interventions are not well documented

Owner Factors

• Owner compliance and financial constraints may limit treatment options
• Owner perception of pain and quality of life may differ from objective assessments
• Cultural and personal beliefs may influence treatment decisions

Practice Setting Limitations

• Access to specialists, advanced imaging, and rehabilitation facilities varies by location
• Time constraints in general practice may limit ability to implement comprehensive monitoring
• Cost of advanced diagnostics and therapies may be prohibitive for some clients

Despite these limitations, the decision framework provides a practical, evidence-informed approach to OA management that can be adapted to individual patients and practice settings. Regular reassessment and adjustment based on objective outcomes remain the cornerstone of effective OA management.

Frequently Asked Questions

What are the earliest signs of osteoarthritis in dogs?

The earliest signs of OA in dogs are often subtle and may be overlooked by owners. These include stiffness after rest, particularly in the morning or after a nap, a slight decrease in activity level, reluctance to jump onto furniture or into the car, and a change in gait, such as a subtle limp or a shortened stride. Owners may also notice that their dog is less enthusiastic about walks or playtime. A study published in the Journal of Small Animal Practice highlighted the use of owner-reported questionnaires to identify these early signs (Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests, Journal of Small Animal Practice, 2022, https://pubmed.ncbi.nlm.nih.gov/35385129).

How is canine osteoarthritis diagnosed?

The diagnosis of canine OA is based on a combination of history, physical examination, and diagnostic imaging. The veterinarian will take a detailed history from the owner, focusing on changes in activity, lameness, and stiffness. A complete orthopedic examination is performed to assess each joint for pain, swelling, crepitus, and range of motion. Radiographs are the most common imaging modality used to confirm the diagnosis and assess the severity of joint changes. In some cases, advanced imaging such as CT or MRI may be recommended. The Merck Veterinary Manual provides comprehensive information on the diagnostic approach to OA (Merck Veterinary Manual, https://www.merckvetmanual.com/).

What is the best treatment for osteoarthritis in dogs?

There is no single best treatment for OA in dogs. The most effective approach is multimodal management, which combines pharmacologic and non-pharmacologic therapies tailored to the individual patient. This typically includes NSAIDs for pain and inflammation, weight management if the dog is overweight, joint supplements, physical therapy, and environmental modifications. In severe cases, surgical options such as joint replacement may be considered. The goal is to control pain, improve function, and maintain quality of life.

Are joint supplements effective for dogs with osteoarthritis?

The evidence for the efficacy of joint supplements in dogs with OA is mixed. Some studies have shown benefit, while others have not. A study published in Frontiers in Veterinary Science evaluated a joint supplement containing eggshell membrane and found it improved mobility in dogs with OA (Efficacy of a joint supplement containing eggshell membrane among other ingredients to improve the mobility of dogs with osteoarthritis: a multicenter double-blind randomized placebo-controlled study, Frontiers in Veterinary Science, 2025, https://doi.org/10.3389/fvets.2025.1561793). Another study compared an oral joint supplement to carprofen in working dogs with hip OA (Effect of an Oral Joint Supplement When Compared to Carprofen in the Management of Hip Osteoarthritis in Working Dogs, Topics in Companion Animal Medicine, 2017, https://doi.org/10.1053/j.tcam.2017.10.003). While supplements may be beneficial for some dogs, they should not be used as a substitute for proven therapies like NSAIDs and weight management.

Can diet help manage osteoarthritis in dogs?

Yes, diet plays an important role in managing OA in dogs. Weight management is critical, as excess body weight places additional stress on joints and contributes to inflammation. A controlled weight loss program can significantly improve clinical signs. Additionally, diets formulated for joint health often contain omega-3 fatty acids, which have anti-inflammatory properties, and other ingredients such as glucosamine and chondroitin sulfate. The Merck Veterinary Manual provides guidance on nutritional management of OA (Merck Veterinary Manual, https://www.merckvetmanual.com/).

What are the risks of NSAID use in dogs with osteoarthritis?

NSAIDs are effective for managing pain and inflammation in dogs with OA, but they carry potential risks. The most common adverse effects are gastrointestinal, including vomiting, diarrhea, and loss of appetite. More serious risks include gastrointestinal ulceration, renal toxicity, and hepatotoxicity. These risks are higher in dogs with pre-existing renal, hepatic, or gastrointestinal disease, and in those receiving concurrent medications such as corticosteroids or other NSAIDs. Baseline blood work and urinalysis are recommended before starting NSAID therapy, and periodic monitoring is advised during long-term use. The Merck Veterinary Manual provides detailed information on NSAID safety (Merck Veterinary Manual, https://www.merckvetmanual.com/).

When should surgery be considered for a dog with osteoarthritis?

Surgery is typically considered for dogs with severe OA that is not adequately controlled with medical management, or for those with an underlying condition that can be surgically corrected. Examples include dogs with hip dysplasia that may benefit from total hip replacement, dogs with cranial cruciate ligament rupture that may benefit from TPLO, or dogs with end-stage joint disease that may benefit from arthrodesis or amputation. The decision to pursue surgery should be made on a case-by-case basis, in consultation with a veterinary orthopedic specialist.

How can I monitor my dog's response to osteoarthritis treatment?

Monitoring your dog's response to OA treatment involves regular assessments of pain, function, and quality of life. Your veterinarian may use a validated pain assessment tool, such as the Canine Brief Pain Inventory (CBPI), to track changes over time. You can also observe your dog at home for changes in activity level, willingness to play, ease of rising, and overall demeanor. Keeping a journal of these observations can be helpful. Regular recheck examinations with your veterinarian are essential to adjust the treatment plan as needed.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Arthritis In Dogs Symptoms And Diagnosis
• Canine Hyperadrenocorticism Cushings Diagnostic Management

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain.. Pain, 2020.
• Diagnosis and treatment of osteoarthritis.. Topics in companion animal medicine, 2010.
• Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs.. Scientific reports, 2024.
• Canine Elbow Dysplasia: Medial Compartment Disease and Osteoarthritis.. The Veterinary clinics of North America. Small animal practice, 2021.
• Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests.. The Journal of small animal practice, 2022.
• Canine synovial fluid biomarkers for early detection and monitoring of osteoarthritis.. The Veterinary record, 2017.
• Demographic factors associated with joint supplement use in dogs from the Dog Aging Project. Frontiers in Veterinary Science, 2022.
• Efficacy of a joint supplement containing eggshell membrane among other ingredients to improve the mobility of dogs with osteoarthritis: a multicenter double-blind randomized placebo-controlled study. Frontiers in Veterinary Science, 2025.
• Effect of an Oral Joint Supplement When Compared to Carprofen in the Management of Hip Osteoarthritis in Working Dogs. Topics in Companion Animal Medicine, 2017.
• Acute manganese toxicosis related to joint health supplement ingestion in two dogs. Topics in Companion Animal Medicine, 2024.
• Pharmacokinetic analysis of an oral multicomponent joint dietary supplement (Phycox®) in dogs. Pharmaceutics, 2017.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.